Melatonin in cancer treatment
暂无分享,去创建一个
[1] A. Seely,et al. Melatonin as Adjuvant Cancer Care With and Without Chemotherapy , 2012, Integrative cancer therapies.
[2] C. Duan,et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials , 2012, Cancer Chemotherapy and Pharmacology.
[3] R. Reiter,et al. Clinical uses of melatonin: evaluation of human trials. , 2010, Current medicinal chemistry.
[4] Nihal Ahmad,et al. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer , 2010, Journal of pineal research.
[5] J. Jacobson,et al. Use of antioxidant supplements during breast cancer treatment: a comprehensive review , 2009, Breast Cancer Research and Treatment.
[6] D. Skene,et al. Physiology and pharmacology of melatonin in relation to biological rhythms , 2009, Pharmacological reports : PR.
[7] R. Reiter,et al. Role of melatonin in the epigenetic regulation of breast cancer , 2009, Breast Cancer Research and Treatment.
[8] M. Melan,et al. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives , 2009, Expert Reviews in Molecular Medicine.
[9] J. Boutin,et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? , 2008, British journal of pharmacology.
[10] Douglas G. Altman,et al. Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .
[11] D. Cardinali,et al. Melatonergic Drugs in Clinical Practice , 2008, Arzneimittel-Forschung (Drug Research).
[12] Robert A Newman,et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. , 2007, Cancer treatment reviews.
[13] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[14] S. V. Anisimov,et al. Melatonin as antioxidant, geroprotector and anticarcinogen. , 2006, Biochimica et biophysica acta.
[15] Nicholas M. Radio,et al. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade , 2006, Journal of pineal research.
[16] G. Guyatt,et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis , 2005, Journal of pineal research.
[17] Simon G. Thompson,et al. Meta‐Analysis of Clinical Trials , 2005 .
[18] Antoine Martin,et al. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague–Dawley rat , 2005, Breast Cancer Research.
[19] R. Reiter,et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism , 2005, The Prostate.
[20] C. Martínez-Campa,et al. Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin* , 2004, Journal of Biological Chemistry.
[21] Josep M. Guerrero,et al. Melatonin inhibits telomerase activity in the MCF‐7 tumor cell line both in vivo and in vitro , 2003, Journal of pineal research.
[22] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[23] R. Reiter,et al. Melatonin Reduces Oxidant Damage and Promotes Mitochondrial Respiration , 2002, Annals of the New York Academy of Sciences.
[24] R. Reiter,et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. , 2002, Current topics in medicinal chemistry.
[25] S. Cos,et al. Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19) , 2001, Melanoma research.
[26] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[27] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[28] M. D. Mediavilla,et al. Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N‐rasproto‐oncogene , 1997, Journal of pineal research.
[29] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[30] A. Lerner,et al. ISOLATION OF MELATONIN, THE PINEAL GLAND FACTOR THAT LIGHTENS MELANOCYTES1 , 1958 .
[31] L. Fuentes-Broto,et al. Melatonin: a multitasking molecule. , 2010, Progress in brain research.
[32] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.